Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788691 · ClinicalTrials.gov registry record · Phase 2
Luspatercept for Clonal Cytopenias of Uncertain Significance
A Phase 2 study of Anemia and Thrombocytopenia, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06788691: Recruiting Phase 2 study of Anemia and Thrombocytopenia, sponsored by Weill Medical College of Cornell University.
NCT06788691 is a Phase 2 study of Anemia and Thrombocytopenia that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 50 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06788691, a Phase 2 study of Anemia and Thrombocytopenia, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.
Primary Outcome
Adapted from International Working Group (IWG) 2018 response definition for Myelodysplastic Syndromes
Conditions Studied
Interventions
- DRUG Luspatercept
Study Locations (1)
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What NCT06788691 shows while recruiting
NCT06788691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (88% lower).
The record links to 5 conditions, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which Luspatercept is the first listed.
NCT06788691 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06788691 about?
NCT06788691 is a clinical study titled "Luspatercept for Clonal Cytopenias of Uncertain Significance". The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blo...
What is the current status of trial NCT06788691?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-03-25. Estimated completion is 2028-02.
What conditions does trial NCT06788691 study?
This clinical trial studies the following conditions: Anemia, Thrombocytopenia, Neutropenia, Leukopenia, CCUS Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT06788691?
The interventions under investigation include: Luspatercept (DRUG).
Who is sponsoring clinical trial NCT06788691?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06788691 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06788691's enrollment target sits among peer trials
50 58th of 72 higher than 14 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI